Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

IceCure Medical Ltd.
Next earnings Aug 3, 2026 · consensus $-1.53 EPS, $1.48M rev
Unprofitable (net margin -445.6%).
Weak on both the fundamentals and the price — little to like at the current level.
IceCure Medical Ltd. shows $3.38M in FY2025 revenue (+2.7% YoY), a -445.6% net margin, and -166.4% ROE.
Sources: SEC EDGAR (CIK 0001584371, latest 6-K filed 2026-06-18) · EODHD · as of 6/20/2026, 7:28:01 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $4.14M | $3.08M | $3.23M | $3.29M | $3.38M |
| Gross profit | $2.19M | $1.45M | $1.30M | $1.45M | $1.23M |
| Operating income | -$9.72M | -$16.7M | -$15.6M | -$15.7M | -$15.1M |
| Net income | -$9.89M | -$17.0M | -$14.7M | -$15.3M | -$15.1M |
| Diluted EPS | $0.35 | $0.46 | $0.32 | $0.30 | $0.24 |
| Net margin | -239.1% | -550.3% | -453.8% | -465.5% | -445.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.